Brief: Patent Approved In Japan For Isofol's Drug Candidate Arfolitixorin

Isofol Medical AB (publ)

20/12/2019 10:46

Dec 20 (Reuters) - Isofol Medical AB (publ)  ISOFOL.ST :
    * PATENT APPROVED IN JAPAN FOR ISOFOL'S DRUG CANDIDATE
ARFOLITIXORIN
    * PATENT COVERING ACTIVE PHARMACEUTICAL INGREDIENT (API),
ARFOLITIXORIN HEMISULFATE, IN ISOFOL'S DRUG CANDIDATE HAS BEEN
APPROVED BY JAPANENSE PATENT OFFICE
    * PATENT WILL BE INSTRUMENTAL IN SUPPORTING A FUTURE
COMMERCIALIZATION OF ARFOLITIXORIN IN JAPANESE MARKET
    * PATENT IS VALID UNTIL 2034
    * ARFOLITIXORIN IS CURRENTLY BEING STUDIED IN ONGOING GLOBAL
PHASE
3 STUDY IN PATIENTS WITH METASTATIC COLORECTAL CANCER, INCLUDING
SITES IN JAPAN

Source text for Eikon:  ID:nWkr46sV6Z 
Further company coverage:  ISOFOL.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))